The E.Coli derived 35.5 kDa recombinant protein contains the HHV-4 Early Antigen Type D, C-terminus regions amiaqno acids 306-390.
> 95%, based on SDS PAGE
Each vial contains 100 μg of lyophilized protein in 50mM Tris-HCl, 10mM glutation, 60mM NaCl, 0.5% sarcosyl and 50% glycerol.
2-8°C short term, -20°C long term
The Epstein–Barr virus (EBV), also called human herpesvirus 4 (HHV-4), is a virus of the herpes family and is one of the most common viruses in humans. It is best known as the cause of infectious mononucleosis (glandular fever). It is also associated with particular forms of cancer, such as Hodgkin's lymphoma, Burkitt's lymphoma, nasopharyngeal carcinoma, and central nervous system lymphomas associated with HIV. There is evidence that infection with the virus is associated with a higher risk of certain autoimmune diseases, especially dermatomyositis, systemic lupus erythematosus, rheumatoid arthritis and multiple sclerosis. Infection with EBV occurs by the oral transfer of saliva
Epstein-Barr virus (EBV) early antigens are a group of non-structural proteins, the synthesis of which do not require viral DNA replication. At least two forms of early antigen have been identified on the basis of their distribution in the cell, namely diffuse and restricted. The early antigen diffuse is expressed during the early lytic phase of virus replication, most notably in keratinocytes of hairy cell leukoplakia.
Epstein–Barr virus; Herpesviridae; Gammaherpesvirinae; Lymphocryptovirus; Human herpesvirus 4; HHV-4; EBV; EBV Early Antigen; Epstein–Barr virus Early Antigen; HHV-4 Early Antigen; Human herpesvirus 4 Early Antigen